Summary Microcolonies were obtained by culturing cells of two human osteosarcoma lines (OHS and KPDX) and one human melanoma line (WIX-c) for either 24 or 72 h. The microcolonies were treated with either a-particle radiation emitted by the 2"'At-labelled monoclonal antibody (MAb) Compounds labelled with the a-particle emitter 2"'At have for some time been preclinically investigated as a means for irradiation of tumour cells (Bloomer et al., 1981; Brown et al., 1981; Vaughan et al., 1981 Vaughan et al., , 1982 Harrison & Royle, 1987; Link et al., 1989) . Although therapeutic effects have been achieved with compartmentally delivered non-specific 2"'At preparations in murine models (Bloomer et al., 1984; Vergote et al., 1992) , the use of 2"'At-labelled compounds with some degree of selective tumour uptake seems to be the most promising strategy (Humm, 1987; Humm & Chin, 1993) . The therapeutic potential of a-emitters is increased when they are coupled to molecules with high tumour affinity because of the short range and high ionisation density of a-particles (Brown, 1986; Kozak et al., 1986; Kurtzman et al., 1988; Macklis et al., 1989) .
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We have recently studied the cytotoxicity of 2"At-TP-3 monoclonal antibody (MAb) on single-cell suspensions of three human osteosarcoma cell lines (OHS, SAOS and KPDX) (Larsen et al., 1994) . The study showed that the sensitivity to 2"1At-TP-3 treatment was governed by cellular properties other than those governing sensitivity to treatment with external beam X-rays. The cellular property most important for sensitivity to 21 At-TP-3 was the antigen density. The cell inactivation was found to increase substantially with increasing specific activity of the 21 At-TP-3 preparation.
At high specific activities, the cytotoxic effect of 2"1At-TP-3 was significantly higher than that of non-specific 21 Atlab.elled bovine serum albumin (BSA). It was concluded that 21 At-TP-3 of high specific activity may have the potential to give clinically favourable therapeutic ratios in the treatment of osteosarcoma.
The clinical conditions for many types of cancer are normally very different from the conditions in the single-cell suspension model. Osteosarcoma, for instance, has a strong tendency to metastasise by cells being trapped in the bone marrow sinusoids and lung capillaries. Cells in microcolonies infiltrating or growing adjacent to normal tissue will have binding kinetic conditions different from free-floating single cells. Steric hindrance from adjacent cells may reduce the number of antigens available for circulating MAbs and, hence, reduce the potential of radioimmunotherapy (RIT).
On the other hand, radiation cross-fire from radiolabelled antibody molecules bound to antigens of neighbouring cells may enhance the efficacy of RIT against tumour cell colonies.
In the present paper we have extended our in vitro investigation of a-particle RIT from the single-cell suspension model to a surface-deposited microcolony model. A surfacedeposited microcolony model was chosen rather than a multicellular spheroid model to avoid the large penetration barrier for MAbs usually seen in spheroids. We used two human osteosarcoma cell lines (OHS and KPDX) with very different antigen expression, and one human malignant melanoma cell line (WIX-c) with no significant antigen expression for the sarcoma-associated MAb TP-3 . Microcolonies were grown on a plastic surface in tissue culture flasks. Inactivation was studied following treatment with 21 At-TP-3 MAb, free 2"'At, 21'At-BSA and external beam X-rays. The objective of this study was to measure and quantify the therapeutic gain from 21'At-labelled MAb on antigen-positive versus antigen-negative microcolonies and to determine some parameters important for RIT of tumour micrometastases.
Materials and methods

Cell lines
The two human osteosarcoma cell lines, OHS and KPDX (Bruland et al., 1985; Fodstad et al., 1986) , and the human melanoma cell line, WIX-c (Rofstad et al., 1991) , have been described in detail previously. WIX-c is more resistant to X-rays than OHS and KPDX. The X-ray survival curve parameters have been found to be: Do = 0.60 ± 0.03 Gy, n=9.9±2.2 (OHS); D0=0.82±0.lOGy, n=3.7±1.2 (KPDX) (Larsen et al., 1994) ; and Do = 0.98 ± 0.04 Gy, n = 2.9 ± 1.1 (WIX-c) (Rofstad, 1992) .
The cell lines were cultured in monolayer in RPMI-1640 medium (25 mM HEPES and L-glutamine) supplemented with 13% fetal calf serum, 250 mg 1' penicillin and 50 mg 1' streptomycin. The cells were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide in air and subcultured every 5-7 days after treatment with 0.05% trypsin/0.02% EDTA. Cells in passages 50-100 in vitro were used in the present work. The cell lines were found to be free from Mycoplasma contamination by using the Hoechst fluorescence and the mycotrim methods.
Monoclonal antibody and antigen expression The MAb TP-3 of subclass IgG2b, which recognises an 80 kDa antigen commonly expressed on sarcoma cells (Bruland et al., 1988) , was used. Production and purification have been described elsewhere . The average numbers of antigens per cell were 7.4 x 105 and 1.2 x 105 for OHS and KPDX respectively (Larsen et al., 1994) . WIX-c had no significant antigen expression for TP-3.
Production of 21'At 21'At (half-life 7.2 h) was produced by the 2'Bi(a,2n)2"1At reaction at the cyclotron at Oslo University. After separation from the bismuth target (Larsen et al., 1993) , the astatine was coupled to the MAb or BSA using the ATE method (Zalutsky & Narula, 1987; Garg et al., 1989) . The procedures for astatine labelling of MAbs have been described in detail elsewhere . The immunoreactivities were measured according to previously published procedures (Lindmo et al., 1984) using OHS cells and were between 55% and 75%. Solutions with free 2"'At were made by dissolving elementary astatine in phosphate-buffered saline (pH 7.4).
Microcolonies
Cells in exponential growth were harvested by trypsinisation and plated in various numbers in 25 cm2 tissue culture flasks (Nunclon) containing 1 x 105 lethally irradiated (30Gy) feeder cells, which were plated 24 h earlier. It was verified experimentally that the feeder cells themselves did not give rise to colonies and that the use of feeder cells increased and stabilised the plating efficiency (PE). The cells were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide in air for 24 or 72 h for formation of microcolonies. The size and growth pattern of the microcolonies were examined by light microscopy before irradiation. Three control flasks and three flasks containing irradiated microcolonies were used to determine each survival level in each experiment.
The number of cells in the microcolonies is presented in Table I . The cells in the 24 h microcolonies were difficult to count exactly because of difficulty in distinguishing viable cells from clonogenically inactive feeder cells. However, a maximum number of cells per colony was established.
External beam X-ray irradiation X-ray irradiation was performed at a dose rate of 4.0 Gy min-' using a Muller RT 250 X-ray unit operated at 250 kV and 20 mA, and with 0.5 mm copper filtration of the beam (Rofstad; 1992) .
Incubation with 21'At preparations After addition of 21 'At preparations, the flasks were incubated on a tilting platform for 90 min. The platform was tilted carefully to avoid loss of cells from the surface-bound microcolonies. The flasks were then placed in an incubator and the 21At was allowed to decay completely. Activity levels of 10, 25 and 50 kBq per ml of tissue culture medium (initial activity) were used. The TGF values were calculated using both 50% and 20% survival of microcolonies. One-way analysis of variance followed by a Student-Newman-Keuls test was used to identify differences between cell lines. A significance level of P = 0.05 was used.
Results
X-ray irradiation
The external beam X-ray survival curves for microcolonies are presented in Figure 1 . The survival increased with microcolony size, in agreement with the increase in cell number per microcolony and the PE of the single cells in the microcolonies. The WIX-c cell line was more resistant than the OHS and KPDX cell lines (P<0.05), which had a similar response to X-rays. The D50 and D20 values for X-ray irradiation of microcolonies are presented in Table II .
21'AT-TP-3 MAb
The microcolony survival curves for OHS, KPDX and WIX-c incubated with 21'At-TP-3 are shown in Figure 2 . Figure 2a presents the curves for 24 h microcolonies incubated with 21 At-TP-3 of 14 MBq mg-'. The curves for 24 h microcolonies exposed to 21 At-TP-3 of 50 MBq mg-' are shown in Figure 2b . A comparison of Figure 2a and 2b shows that the increase in specific activity resulted in reduced regeneration of microcolonies for the OHS line, whereas the KPDX line showed a significant difference only at the 50 kBq ml l medium activity level. In Figure 2c the survival curves for 72 h microcolonies are presented. At the 10 kBq ml-' activity level the difference between the survival of OHS and KPDX was minor. At higher medium activities the OHS line was affected considerably more than the KPDX line. The dose (± s.e.) in Gy to give 50% (D50) and 20% (D20) survival of microcolonies calculated using linear dose-log survival interpolation between experimental points (Figure 1 lower A50 and A20 values than KPDX (P <0.05), and both had significantly lower A50 and A20 values than WIX-c (P <0.05). There was no significant change in survival of 24 h microcolonies of WIX-c caused by the increase in specific activity from 14 MBq mg-' to 50 MBq mg-' of the 2"At-MAb.
21'At-BSA andfree 21'At
The microcolony survival curves for 2"'At-BSA and free 2"At are presented in Figures 3 and 4 . At activity levels of 25 and 50 kBq ml-', free 2"'At was significantly more toxic than 2"'At-BSA (P<0.05). The curves for 24 h microcolonies of WIX-c incubated with 2"At-BSA and 2"At-TP-3 are similar.
A50 and A20 values for the two forms are presented in Table   IV .
Therapeutic gain factor TGF values were calculated for the treatment of OHS and KPDX microcolonies with 2"At-TP-3 MAb by using WIX-c Table III A50 and A20 values for 2"At-TP-3 added to the culture medium of microcolonies (Table V) or treatment with 2"'At-BSA (Table VI) as references. TGFm and TGF20 were consistently above unity and were on average a factor of 1.6 larger for OHS than for KPDX, and this agrees with the higher antigen expression of the OHS cell line. TGF values were also calculated for the non-specific 21'At forms free 2"1At and 2"At-BSA for comparison (Table V) .
There was no significant difference between the two osteosarcoma cell lines. The values were varying from 0.6±0.1 to 1.0 ± 0.3 (mean ± s.e.) and there was no significant difference between free 2"At and 2"'At-BSA.
Discussion
Therapeutic gain measured in vitro reflects to a large extent the experimental conditions. It is noteworthy that the experimental procedures used here did not allow any strong mixing of the cells and the 2"At-MAb preparations, and that the unbound 2"At preparations were allowed to d6cay completely in the growth medium, giving a high non-specific dose to the cells. Nevertheless, significant therapeutic gain was achieved with 2"At-TP-3 on antigen-positive cells. The parameter most strongly influencing the therapeutic gain was the specific activity of the 2"At-MAb preparation. Owing to Added activity (± s.e.) in kBq ml-' in the culture medium to give 50% (A50) and 20% (A20) survival of microcolonies calculated using linear activity-log survival interpolation between experimental points (Figure 2 ). The 21 preparations were allowed to decay completely (> 72 h) before the medium was changed. s.e. values were calculated from the s.e. values of the two nearest experimental points. aThe 20% survival level was outside the region covered by experimental data for WIX-c. 1004 Activity (kBq ml-) Added activity (± s.e.) in kBq ml-' in the culture medium to give 50% (A50) and 20% (A20) survival of microcolonies calculated using linear activity-log survival interpolation between experimental points (Figures 3 and 4) 211At-MAb will therefore increase the therapeutic gain further. The therapeutic gain was in this study measured in two ways. Firstly, TGF values were determined for the antigenpositive cell lines using the antigen-negative cell line as reference. In this case corrections for differences in X-ray sensitivity were included. Secondly, TGF values were determined by comparison of the cytotoxicity of the cell-binding 211At-MAb with that of a non-specific 21'At-protein using the same cell line. The target tissue (OHS and KPDX osteosarcoma microcolonies) was more sensitive to X-rays than the control tissue (WIX-c melanoma microcolonies). A system with resistant tumour cells and sensitive control cells would have given higher therapeutic gain. This is because cell lines generally show less variability in radiation response when treated with high linear energy transfer (LET) radiation, e.g. a-particles and slow neutrons, than when treated with low-LET radiation (Hall, 1988) .
A characteristic that may be important for the therapeutic gain of a-particle RIT is the growth pattern of the cells within a microcolony. Microscopical examinations revealed that the OHS cells tended to grow in a scattered pattern while the KPDX cells tended to grow tightly in the microcolonies. The a-particle intra-colony cross-fire was therefore more important for the KPDX than for the OHS microcolonies. This explains why the 72 h microcolonies had significantly higher TGF values than the 24 h microcolonies for KPDX -but not for OHS.
The experiments with 2"'At-BSA and 21 At-TP-3 on the antigen-free WIX-c cell line show that the change in molecular size from approximate molecular weight (MW) of 66,000 to approximate MW of 160,000 did not influence the cytotoxicity of the 21'At-protein conjugate. Moreover a change in the specific activity of 21 At-TP-3 from 14 to 50MBqmg-' did not change the non-specific cytotoxicity against WIX-c microcolonies significantly. It can therefore be concluded that the cytotoxicity of non-specific 21'At-labelled proteins is not significantly influenced by the size and the specific activity of the 21'At-protein conjugate.
The uptake of radiolabelled MAbs measured in tumours in patients has generally been low (Epenetos et al., 1986) . Clinically, intravenously injected short-lived ax-particleemitting radioimmunoconjugates such as 21 At-TP-3 cannot be expected to give substantial therapeutic gain in the treatment of large solid tumours. The in vitro study presented here indicates, however, that a well-vascularised tumour or micrometastases may be candidates for treatment with 21 AtMAbs, on the conditions that the MAb binds strongly to the tumour cells and has a low cross-reactivity with normal tissue. Further in vivo studies with relevant tumour models are therefore desirable.
